Abstract: Methods for identifying new therapeutic activities for known therapeutic agents, as well as systems for practicing the same, are provided. Aspects of the invention further include are methods and compositions for the treatment of an acute graft rejection (AR).

Abstract: Novel thrombin/prothrombin protease/zymogen variants which have anticoagulation activity and methods of use thereof are disclosed.

Abstract: A microfluidic device comprises pumps, valves, and fluid oscillation dampers. In a device employed for sorting, an entity is flowed by the pump along a flow channel through a detection region to a junction. Based upon an identity of the entity determined in the detection region, a waste or collection valve located on opposite branches of the flow channel at the junction are actuated, thereby routing the entity to either a waste pool or a collection pool. A damper structure may be located between the pump and the junction. The damper reduces the amplitude of oscillation pressure in the flow channel due to operation of the pump, thereby lessening oscillation in velocity of the entity during sorting process. The microfluidic device may be formed in a block of elastomer material, with thin membranes of the elastomer material deflectable into the flow channel to provide pump or valve functionality.

Abstract: The present disclosure provides a cross-linked material comprising conjugates which include two or more separate affinity ligands bound to a non-polymeric framework, wherein the molecular weight of the non-polymeric framework is less than 10,000 Da; and multivalent cross-linking agents that non-covalently bind the affinity ligands of the conjugates and thereby cross-link the conjugates to form a cross-linked material, wherein the non-covalent bonds between the multivalent cross-linking agents and the affinity ligands are competitively dissociated in the presence of excess amounts of a target molecule. The present disclosure also provides methods of making and methods of using these materials. In other aspects, the present disclosure provides exemplary conjugates including conjugates for use in glucose responsive cross-linked materials.

Abstract: A method is provided for preventing rejection by an immune system of a recipient subject of a tissue transplanted from a donor subject into the recipient subject without the need for long-term administration of non-specific immunosuppressive drugs.

Abstract: Methods, assays, and kits for determining a cancer's (e.g., breast cancer) metastatic potential and tumor aggressiveness in a subject (e.g., a human patient) and for measuring a subject's response to cancer therapy involve analyzing expression of Sema7A in a biological sample from the subject, and correlating increased expression of Sema7A in the biological sample compared to a control sample with metastatic potential of the cancer, wherein the expression of Sema7A is linearly proportional to the metastatic potential of the cancer in the subject. These methods, kits and assays provide for individualized diagnosis and treatment options for cancer (e.g., breast cancer) patients. They can be used independently, or can be combined with additional diagnostic tests and/or prognostic methods. Compositions, kits and methods for treating a subject having cancer (e.g., breast cancer) include administering a composition for inhibiting Sema7A expression or activity to the subject.

Abstract: Methods and therapeutic treatments of ocular diseases are provided including applying peg-Arginase I to affected eyes. Methods are provided that simultaneously treat inflammation and neovascularization of eyes while promoting healing. Methods are provided to treat lesions or infections of an eye.

Abstract: Surface-modified polymeric nanoparticles (NPs), compositions for making them, and their use in drug delivery are disclosed.

Abstract: Compositions and methods are disclosed for identifying agents useful for the treatment of proteinopathies.

Abstract: A system and method is provided for magnetic resonance angiography (MRA) that includes performing a pulse sequence using the MRI system, the pulse sequence including a phase-based flow encoding to collect a time-series of image data from the portion of the vasculature of the subject and identifying at least a portion of the time series of image data corresponding to a period of reduced flow through the portion of the vasculature. The portion of the time series of image data is subtracted from the time series of image data to create a time series of images of the portion of the vasculature having background tissue surrounding the portion of the vasculature substantially suppressed.

Abstract: Small molecule inhibitors of Stat3 and their derivatives are disclosed. Also described are methods to inhibit cell growth by use of Stat3 inhibitors, and the use of Stat3 inhibitors for the prevention and/or treatment of cancer. Further, inhibitors of Stat3 that also do not inhibit Stat1 are described as well as their derivatives. Methods of screening additional compounds for Stat3 inhibition activity and/or non-inhibition of Stat1 activity are also described herein.

Abstract: A solution for managing messaging is provided in which an event related to a publisher is identified. In response to the event, a transaction is initiated for processing the event, the event is processed within the transaction, and the transaction is committed after the event is processed. During processing, data corresponding to the event is provided for use by a set of subscribers to the event, and data related to the set of subscribers is identified. In an embodiment, a message broker in a publication and subscribe messaging environment implements the solution in order to be capable of providing the data related to the set of subscribers to the publisher. Use of the transaction ensures that the data related to the set of subscribers accurately represents the set of subscribers at the time that the data corresponding to the event was provided.

Abstract: The present invention relates to novel recombinant polypeptide antigens that may comprise subunit vaccines against rotavirus infection. Further, the present invention relates to methods for use of said antigens in the diagnosis, treatment and prevention of rotavirus infection.

Abstract: An example embodiment relates to a method of manufacturing an array of electric devices that includes attaching a platform including a micro-channel structure to a substrate. The method includes injecting first and second solutions into the micro-channel structure to form at least three liquid film columns, where the first and second solutions include different solvent composition ratios and the liquid columns each, respectfully, include different solvent composition ratios. The method further includes detaching the platform the substrate, removing solvent from the liquid film columns to form thin film columns, and treating the thin film columns under different conditions along a length direction of the thin film columns. The solvent is removed from the thin film columns and the thin film columns are treated under different conditions along a length direction of the thin film columns.

Abstract: Peptides generated from a random library that are bound by a monoclonal antibody to Chlamydial glycolipid exoantigen (GLXA) and thus mimic this antigen are disclosed. Peptides that correspond to antigen-binding regions of an anti-idiotypic antibody (mAb2) specific for anti-GLXA antibody (Ab1) which act as molecular mimics of GLXA are also disclosed used as immunogens to induce broadly reactive genus-specific anti-chlamydial antibodies. These peptides and immunogenic DNA encoding the mAb2-like peptides, microparticle or nanoparticle formulations and other formulations of these peptides are disclosed as are methods for immunizing subjects to obtain genus-specific anti-chlamydial antibodies and to treat or prevent Chlamydia-associated or induced rheumatoid arthritis.

Abstract: An acoustical fluid control mechanism and a method of controlling fluid flow of a working fluid with the acoustical fluid control mechanism are provided. The mechanism comprises a resonance chamber that defines a cavity. The resonance chamber has a port. The cavity is sealed from the ambient but for the port for enabling oscillatory flow of a working fluid into and out of the cavity upon exposure of the resonance chamber to an acoustic signal containing a tone at a frequency that is substantially similar to a particular resonance frequency of the resonance chamber. The mechanism further includes a rectifier for introducing directional bias to the oscillatory flow of the working fluid through the port. The rectifier has an inlet connected to the port and an outlet for transmitting the directional flow of the working fluid away from the cavity. The outlet is in fluid communication with the port of the resonance chamber at least during transmission of the directional flow of the working fluid therethrough.

Abstract: Method, system, and computer program method for detecting pathological fluctuations of physiological signals to diagnose human illness. The method comprises performing a sliding window analysis to find sequences in physiological signal data that match amplitude- and duration-adjusted versions of a template function to within a specified tolerance.

Abstract: A tissue fixation device includes a tack having at least two flexible arms on a first end of said anchor. A deployment device for deploying a tissue fixation device, wherein the deployment device is a deployment gun.

Abstract: The present invention relates to methods of preventing or treating cancer and/or decreasing damage to organs or tissues exposed to hypoxic conditions through the use of agents that modulate the expression or activity of SIRT3.

Abstract: The present invention provides a composition effective for a neurological disease or an autoimmune disease and methods of making and using the same.